Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Cras viverra rhoncus metu
$77.00Add to cartAenean ut commodo justo. Fusce accumsan erat ut purus mollis, quis fermentum magna luctus. Morbi pulvinar augue lorem, quis molestie ipsum dictum non. Donec malesuada fermentum ex non hendrerit. Sed tempor viverra arcu a ultrices. Suspendisse non malesuada massa. Praesent imperdiet rhoncus nunc, vel fringilla enim lacinia quis
-
Quick View
Fusce nec diam et dolor
$45.00Add to cartFusce nec diam et dolor ornare rhoncus nec ut mauris. In eleifend mi in felis dictum fermentum. Morbi vel arcu sit amet dolor venenatis bibendum in eu dui. Nulla velit dolor, imperdiet consectetur luctus ut, faucibus eget est.
-
Quick View
Nunc tempus facilisis
$87.00Add to cartFusce ullamcorper dapibus eleifend. Nullam ornare pulvinar lacinia. Nunc tempus facilisis ullamcorper. Nam sit amet suscipit risus, ut ultricies felis. Vivamus a finibus nisi. Sed quam sem, accumsan eget tristique sit amet, suscipit sit amet augue. Duis dolor dui, sagittis at faucibus ac, varius et sapien.
-
Quick View
Curabitur ultricies ante ultricies blandit
$88.00Add to cartCurabitur ultricies ante ultricies blandit placerat. Phasellus fermentum, ligula sed vestibulum blandit, mi odio laoreet sem, a venenatis tellus felis eu justo. Nullam ut felis et mauris iaculis malesuada. Donec non turpis vel lectus accumsan rutrum. Vestibulum finibus nunc libero, vel dapibus mauris porta vitae.
Reviews
There are no reviews yet.